New York, NY -- (SBWIRE) -- 01/27/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Neuralstem, Inc (NYSEMKT:CUR), Document Security Systems, Inc (NYSEMKT:DSS), Zalicus Inc (NASDAQ:ZLCS)
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) showed a volume of 2.05 million shares by the end of last trade whereas the average volume of the stock remained 3.27 million shares. The stock opened the session at $3.64 but then moved to $3.44. At that price, the stock showed a negative performance of -6.52%. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system.
Will AVNR Get Buyers Even After The Recent Rally? Find Out Here
Neuralstem, Inc (NYSEMKT:CUR) opened the session at $3.22 and closed the session at $3.04. The stock showed a negative performance of -8.16% in previous trading session. Traded with volume of 2.01million shares in the prior session and the average volume of the stock remained 1.07 million shares. Neuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.
Has CUR Found The Bottom And Ready To Gain Momentum? Find Out Here
Document Security Systems, Inc (NYSEMKT:DSS) opened the session at $1.52 and closed the session at $1.60. The stock showed a positive performance of 7.38% in previous trading session. Traded with volume of 1.99 million shares in the prior session and the average volume of the stock remained 1.21 million shares. The beta of the stock remained 0.48. Document Security Systems, Inc. (DSS) develops, markets, secure technologies. The Company specializes in fraud and counterfeit protection for all forms of printed documents and digital information. The Company holds numerous patents for optical deterrent technologies that provide protection of printed information from unauthorized scanning and copying.
Why Should Investors Buy DSS After The Recent Gain? Just Go Here and Find Out
Zalicus Inc (NASDAQ:ZLCS) the stock decreased -9.89% and finished the session at $1.64. Traded with volume of 1.97 million shares in the prior session and the average volume of the stock remained 1.79 million shares. The beta of the stock remained 1.69. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases.
Will ZLCS Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)